Literature DB >> 33665046

Severe Vaso-Occlusive Retinopathy in Systemic Lupus Erythematosus: A Case Series.

Kshitiz Kumar1, Shouvick Dan1, Tushar K Sinha1, Debashish Bhattacharya1.   

Abstract

This study aims to describe the clinical profile of severe vaso-occlusive retinal disorders in patients with systemic lupus erythematosus (SLE) and it is a retrospective case series. The clinical characteristics of three patients with SLE with vascular occlusions in four eyes were described. Branch retinal artery occlusion (BRAO) was present in all three patients with combined non-ischemic central retinal vein occlusion (NICRVO) in one patient and evolving ischemic CRVO in another patient. Additional branch retinal artery insufficiency was observed in the other eye of a patient with BRAO. Antinuclear antibody (ANA) titer was elevated in all patients. One patient had a positive lupus anticoagulant with elevated activated partial thromboplastin time (aPTT), and concurrent homocysteinemia was present in another patient. Intravitreal anti-vascular endothelial growth factor (ranibizumab) injection was administered to two eyes. Intravenous methyl prednisolone (IVMP) injection along with oral azathioprine was used in all patients with the need for anticoagulation in two patients along with SLE treatment. Vision in two eyes did not improve to the functional level despite aggressive therapy. Visually blinding severe vaso-occlusive retinopathy in the form of BRAO with or without CRVO can manifest in patients with SLE. Undetected antiphospholipid syndrome and homocysteinemia may be associated risk factors for such ophthalmic complications.
Copyright © 2021, Kumar et al.

Entities:  

Keywords:  brao; crvo; ranibizumab; systemic lupus erythematosus; vaso-occlusive retinopathy

Year:  2021        PMID: 33665046      PMCID: PMC7920792          DOI: 10.7759/cureus.13019

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  20 in total

1.  Combined retinal artery and vein occlusion in a patient with systemic lupus erythematosus and antiphospholipid syndrome.

Authors:  A Hakan Durukan; Yusuf Akar; M Zeki Bayraktar; Ayhan Dinc; O Faruk Sahin
Journal:  Can J Ophthalmol       Date:  2005-02       Impact factor: 1.882

2.  Bilateral combined central retinal artery and vein occlusion in systemic lupus erythematosus resulting in complete blindness.

Authors:  E Mendrinos; N Mavrakanas; R Kiel; C J Pournaras
Journal:  Eye (Lond)       Date:  2008-06-06       Impact factor: 3.775

3.  Retinal arterial occlusive disease in systemic lupus erythematosus.

Authors:  D Gold; L Feiner; P Henkind
Journal:  Arch Ophthalmol       Date:  1977-09

Review 4.  Systemic lupus erythematosus.

Authors:  J A Mills
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

Review 5.  Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view.

Authors:  Paola Conigliaro; Massimo Cesareo; Maria Sole Chimenti; Paola Triggianese; Claudia Canofari; Carmen Barbato; Clarissa Giannini; Ada Giorgia Salandri; Carlo Nucci; Roberto Perricone
Journal:  Autoimmun Rev       Date:  2019-01-11       Impact factor: 9.754

6.  Acute vision loss in systemic lupus erythematosus: bilateral combined retinal artery and vein occlusion as a catastrophic form of clinical flare.

Authors:  M Akhlaghi; B Abtahi-Naeini; M Pourazizi
Journal:  Lupus       Date:  2017-08-30       Impact factor: 2.911

7.  Bilateral central retinal artery occlusion and vein occlusion complicated by severe choroidopathy in systemic lupus erythematosus.

Authors:  K M Nishiguchi; Y Ito; H Terasaki
Journal:  Lupus       Date:  2013-05-16       Impact factor: 2.911

Review 8.  Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment.

Authors:  Alicia Au; Justin O'Day
Journal:  Clin Exp Ophthalmol       Date:  2004-02       Impact factor: 4.207

9.  The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness.

Authors:  Borja Gracia-Tello; Amara Ezeonyeji; David Isenberg
Journal:  Lupus Sci Med       Date:  2017-02-02

10.  2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Authors:  Martin Aringer; Karen Costenbader; David Daikh; Ralph Brinks; Marta Mosca; Rosalind Ramsey-Goldman; Josef S Smolen; David Wofsy; Dimitrios T Boumpas; Diane L Kamen; David Jayne; Ricard Cervera; Nathalie Costedoat-Chalumeau; Betty Diamond; Dafna D Gladman; Bevra Hahn; Falk Hiepe; Søren Jacobsen; Dinesh Khanna; Kirsten Lerstrøm; Elena Massarotti; Joseph McCune; Guillermo Ruiz-Irastorza; Jorge Sanchez-Guerrero; Matthias Schneider; Murray Urowitz; George Bertsias; Bimba F Hoyer; Nicolai Leuchten; Chiara Tani; Sara K Tedeschi; Zahi Touma; Gabriela Schmajuk; Branimir Anic; Florence Assan; Tak Mao Chan; Ann Elaine Clarke; Mary K Crow; László Czirják; Andrea Doria; Winfried Graninger; Bernadett Halda-Kiss; Sarfaraz Hasni; Peter M Izmirly; Michelle Jung; Gábor Kumánovics; Xavier Mariette; Ivan Padjen; José M Pego-Reigosa; Juanita Romero-Diaz; Íñigo Rúa-Figueroa Fernández; Raphaèle Seror; Georg H Stummvoll; Yoshiya Tanaka; Maria G Tektonidou; Carlos Vasconcelos; Edward M Vital; Daniel J Wallace; Sule Yavuz; Pier Luigi Meroni; Marvin J Fritzler; Ray Naden; Thomas Dörner; Sindhu R Johnson
Journal:  Arthritis Rheumatol       Date:  2019-08-06       Impact factor: 15.483

View more
  2 in total

1.  Unilateral branch retinal artery occlusion in a patient with systemic lupus erythematosus: A case report.

Authors:  Linglin Zhang; Chaoqiang Guan; Zuke Ye; Yan Lu
Journal:  Medicine (Baltimore)       Date:  2022-03-11       Impact factor: 1.817

2.  Case Report: Recurrent retinal vein occlusion as the first clinical manifestation of systemic lupus erythematosus in a male patient.

Authors:  Marwa Ben Brahim; Sondes Arfa; Fadia Boubaker; Jihen Chelly; Wafa Ammari; Sonia Hammami; Fatma Arbi; Olfa Berriche
Journal:  F1000Res       Date:  2021-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.